<DOC>
	<DOC>NCT00448292</DOC>
	<brief_summary>The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.</brief_summary>
	<brief_title>A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Patients with major depressive disorder who meet all of the eligibility criteria will be randomly assigned to receive twice daily doses of either placebo or PRX-00023. Study drug will be taken for up to approximately 9 weeks. Patients will have periodic office visits for the purpose of monitoring safety and tolerability, as well as efficacy assessments.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Naluzotan</mesh_term>
	<criteria>Key Diagnosis of major depressive disorder Key Females who are pregnant or nursing Electroconvulsive therapy within previous year Type 1 diabetes or uncontrolled type 2 diabetes HIV, Hepatitis B or Hepatitis C Use of illegal drugs, history of drug abuse, and/or alcohol dependence Clinically significant abnormal lab results Other protocoldefined eligibility criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Major Depression</keyword>
	<keyword>MDD</keyword>
</DOC>